Compare Plby Group Inc (PLBY) vs 10X Genomics Inc (TXG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Plby Group Inc vs 10X Genomics Inc — how do they compare? Plby Group Inc trades at $1.16 (market cap $141.97M), while 10X Genomics Inc trades at $67.8 (market cap $8.55B). The key difference: 10X Genomics Inc is far larger — about 60.2× Plby Group Inc's market cap, and 10X Genomics Inc is trading nearer its 52-week high, Plby Group Inc nearer its low. Which is the better fit depends on your goals.
| PLBY | TXG | |
|---|---|---|
Market Cap | $141.97M | $8.55B |
Sector | Consumer Cyclical | Health |
52-Week High | $2.71 | $67.29 |
52-Week Low | $1.11 | $11.34 |
Enterprise Value | $287.56M | $8.08B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
PLBY Group trades at $1.18, showing modest daily gains but remains in a technical downtrend. The company demonstrates improving fundamentals with revenue stabilizing around $120M and narrowing losses, though profitability remains elusive. Recent positive developments include Q2 2026 earnings beat, inclusion in Russell indexes, and strategic share repurchases. Analyst sentiment leans bullish with 75% buy ratings, yet technical indicators signal caution with bearish moving averages.
The outlook suggests cautious optimism as PLBY transitions toward profitability, supported by licensing growth and cost management. Key opportunities include brand monetization and market share gains, while risks involve high debt levels, negative equity, and competitive pressures. Investors should monitor execution on profitability targets and debt reduction progress for sustained recovery.
TXG trades at $65.60, up 4.71% today, with strong technical momentum showing bullish moving averages and key support at $63. Fundamentally, the company demonstrates improving trends with Q2 2026 earnings beating estimates and revenue growth guidance raised, though profitability remains negative with a -12.18% net margin. Recent patent victory against Parse Biosciences strengthens competitive positioning.
The outlook remains cautiously optimistic with analyst consensus at 45% buy ratings and $50.78 price target. Key opportunities include Atera platform adoption and consumables growth, while risks center on valuation premiums and ongoing profitability challenges. The stock trades near resistance at $67 with institutional interest showing mixed signals.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Plby Group Inc
PLBY Group Inc is a pleasure and leisure company. The company's segment includes Licensing, Direct-to-Consumer, and Digital Subscriptions and Content. It generates maximum revenue from the Direct-to-Consumer segment. Direct-to-Consumer operations include consumer products sold through third-party retailers or online direct-to-customer. Geographically, it derives a majority of revenue from the United States.
Read more on PLBY →About 10X Genomics Inc
10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.
Read more on TXG →
